A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies

Archives of Toxicology

Volumn 88, Issue 5, 2014, Pages 1083-1095

  Ramaiahgari, Sreenivasa C ^a   Den Braver, Michiel W ^b   Herpers, Bram ^a,d   Terpstra, Valeska ^c   Commandeur, Jan N M ^b   Van De Water, Bob ^a   Price, Leo S ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d OcellO BV   (Netherlands)

Author keywords

Alternative models; Bile canaliculi; CYP450 enzymes; Drug metabolism; Drug induced liver injury

Indexed keywords

ALBUMIN; BUFURALOL; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DICLOFENAC; DRUG METABOLIZING ENZYME; MIDAZOLAM; TRANSCRIPTION FACTOR; TROVAFLOXACIN; UREA; XENOBIOTIC AGENT; ALBUMINOID; CYTOCHROME P450;

ARTICLE; CELL DIFFERENTIATION; CELL JUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG METABOLISM; EXTRACELLULAR MATRIX; HEPG2 CELL LINE; HIGH THROUGHPUT SCREENING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROGEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MONOLAYER CULTURE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THREE DIMENSIONAL IMAGING; TOXIC HEPATITIS; TOXICITY; TUMOR SPHEROID; DRUG EFFECTS; DRUG INACTIVATION; GENETICS; INTRAHEPATIC BILE DUCT; LIVER; METABOLISM; MULTICELLULAR SPHEROID; PROCEDURES; TOXICITY TESTING;

ALBUMINS; BILE CANALICULI; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INACTIVATION, METABOLIC; LIVER; SPHEROIDS, CELLULAR; TOXICITY TESTS; UREA;

EID: 84901339650     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1215-9     Document Type: Article

References (50)

1. Abe K, Bridges AS, Brouwer KL (2009) Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 37(3):447-452
2. Asthana A, Kisaalita WS (2012) Microtissue size and hypoxia in HTS with 3D cultures. Drug Discov Today 17(15-16):810-817
3. Bahrami A, Truong LD, Ro JY (2008) Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 132(3):326-348 (Pubitemid 351328809)
4. Beggs KM, Fullerton AM, Miyakawa K, Ganey PE, Roth RA (2014) Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction. Toxicol Sci 137(1):91-101
5. Chen G, Li S, Dong X et al (2012) Investigation of testosterone, androstenone, and estradiol metabolism in HepG2 cells and primary culture pig hepatocytes and their effects on 17betaHSD7 gene expression. PLoS ONE 7(12):e52255
6. Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR (2005) Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab Dispos 33(6):714-718 (Pubitemid 40686622)
7. de Waart DR, Hausler S, Vlaming ML et al (2010) Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein. J Pharmacol Exp Ther 334(1):78-86
8. di Masi A, De Marinis E, Ascenzi P, Marino M (2009) Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Asp Med 30(5):297-343
9. Fattinger K, Funk C, Pantze M et al (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223-231 (Pubitemid 32382504)
10. FDA guidance for drug interactions-study design, data analysis, implications for dosing and labeling recommendations, CDER, 2012 Feb. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf. Accessed: 31 Jan 2014
11. Fey SJ, Wrzesinski K (2012) Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicol Sci 127(2):403-411
12. Fredriksson L, Herpers B, Benedetti G et al (2011) Diclofenac inhibits tumor necrosis factor-α-induced nuclear factor-κB activation causing synergistic hepatocyte apoptosis. Hepatology 53(6):2027-2041
13. Godoy P, Hewitt NJ, Albrecht U et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87(8):1315-1530
14. Guengerich FP (2006) Cytochrome P450 s and other enzymes in drug metabolism and toxicity. AAPS J 8(1):E101-E111
15. Guideline on the investigation of drug interactions. European Medicines Agency, 2012 June 21. http://www.ema.europa.eu/docs/ en-GB/document-library/ Scientific-guideline/2012/07/WC500129606.pdf). Accessed 31 Jan 2014
16. Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F (2013) 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci 133(1):67-78
17. Guo L, Dial S, Shi L et al (2011) Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 39(3):528-538
18. Haouzi D, Baghdiguian S, Granier G, Travo P, Mangeat P, Hibner U (2005) Three-dimensional polarization sensitizes hepatocytes to Fas/CD95 apoptotic signalling. J Cell Sci 118(Pt 12):2763-2773 (Pubitemid 40932900)
19. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148(1):3-15
20. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, Brouwer KL (2004) P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 21(7):1294-1302 (Pubitemid 38954216)
21. Jedlitschky G, Hoffmann U, Kroemer HK (2006) Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2(3):351-366 (Pubitemid 46141403)
22. Kanno Y, Inouye Y (2010) A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells. J Toxicol Sci 35(4):515-525
23. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK (2003) Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 83(2):173-180 (Pubitemid 36734131)
24. Khetani SR, Kanchagar C, Ukairo O et al (2013) Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 132(1):107-117
25. Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 94(2):261-271 (Pubitemid 44817142)
26. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T (2005) Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 57(5):573-578 (Pubitemid 40562396)
27. Kublbeck J, Jyrkkarinne J, Molnar F et al (2011) New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol Pharm 8(6):2424-2433
28. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13(4):343-368
29. LeCluyse EL, Audus KL, Hochman JH (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266(6 Pt 1):C1764-C1774 (Pubitemid 24220826)
30. LeCluyse EL, Witek RP, Andersen ME, Powers MJ (2012) Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42(6):501-548
31. MacDonald JS, Robertson RT (2009) Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci 110(1):40-46
32. Madan A, Graham RA, Carroll KM et al (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31(4):421-431 (Pubitemid 36378519)
33. Malinen MM, Palokangas H, Yliperttula M, Urtti A (2012) Peptide nanofiber hydrogel induces formation of bile canaliculi structures in three-dimensional hepatic cell culture. Tissue Eng Part A 18:2418-2425
34. Matsui H, Takeuchi S, Osada T, Fujii T, Sakai Y (2012) Enhanced bile canaliculi formation enabling direct recovery of biliary metabolites of hepatocytes in 3D collagen gel microcavities. Lab Chip 12(10):1857-1864
35. Mueller D, Kramer L, Hoffmann E, Klein S, Noor F (2014) 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicol In Vitro 28(1):104-112
36. Nakamura K, Mizutani R, Sanbe A et al (2011) Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. J Biosci Bioeng 111(1):78-84
37. Naspinski C, Gu X, Zhou G-D, Mertens-Talcott SU, Donnelly KC, Tian Y (2008) Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. Toxicol Sci 104(1):67-73 (Pubitemid 351859029)
38. Ng S, Han R, Chang S et al (2006) Improved hepatocyte excretory function by immediate presentation of polarity cues. Tissue Eng 12(8):2181-2191 (Pubitemid 44734977)
39. Silva MF, Aires CC, Luis PB et al (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31(2):205-216
40. Sweet DH (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204(3):198-215
41. Tang W, Abbott FS (1996) Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates. Chem Res Toxicol 9(2):517-526
42. Tostoes RM, Leite SB, Serra M et al (2012) Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 55(4):1227-1236
43. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19:821-832
44. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36(1):164-172 (Pubitemid 34700774)
45. Vincent J, Teng R, Dalvie DK, Friedman HL (1998) Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am J Surg 176(Suppl 6A):8S-13S (Pubitemid 29074957)
46. Wang L, Boyer JL (2004) The maintenance and generation of membrane polarity in hepatocytes. Hepatology 39(4):892-899 (Pubitemid 38428924)
47. Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4(10):825-833 (Pubitemid 41553963)
48. Wilkening S, Stahl F, Bader A (2003) Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 31(8):1035-1042 (Pubitemid 36975674)
49. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105(1):97-105
50. Zhang F, Xu R, Zhao M-j (2010) QSG-7701 human hepatocytes form polarized acini in three-dimensional culture. J Cell Biochem 110(5):1175-1186